ILiAD Biotechnologies Announces Planned Collaboration with Emmes Group, a New Mountain Capital Portfolio Company, to Conduct Upcoming Phase III Clinical Trials of BPZE1, the Leading Next-Generation Pertussis Vaccine
ILiAD Biotechnologies, LLC
Biotechnology Research
Weston, Florida 729 followers
ILiAD is advancing the next generation pertussis vaccine for the prevention of whooping cough.
About us
ILiAD Biotechnologies is utilizing its B-Tech vector platform to develop next generation vaccines to eradicate infectious diseases and improve lives. Its lead candidate, BPZE1, which has completed Phase 2 clinical trials, is the most advanced next generation vaccine for the prevention of whooping cough, a serious illness caused by Bordetella pertussis.
- Website
-
http://www.iliadbio.com
External link for ILiAD Biotechnologies, LLC
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Weston, Florida
- Type
- Privately Held
- Founded
- 2012
- Specialties
- Infectious Diseases and Pediatrics
Locations
-
Primary
Get directions
4581 Weston Road
Suite 260
Weston, Florida 33331, US
Employees at ILiAD Biotechnologies, LLC
Updates
-
ILiAD Biotechnologies Reports Positive Topline Interim Results from Phase 2b School-Age Trial of BPZE1 Pertussis Vaccine
ILiAD Biotechnologies Reports Positive Topline Interim Results from Phase 2b School-Age Trial of BPZE1 Pertussis Vaccine
businesswire.com
-
ILiAD Biotechnologies Announces Presentation at the 2023 World Vaccine Congress in Barcelona https://lnkd.in/ggH_9TmH
-
-
ILiAD Biotechnologies Reports First-ever Demonstration of Protection Against B. pertussis Colonization in Phase 2b Human Challenge Study of BPZE1 Vaccine
ILiAD Biotechnologies Reports First-ever Demonstration of Protection Against B. pertussis Colonization in Phase 2b Human Challenge Study of BPZE1 Vaccine
businesswire.com